Hereditary common cancers: molecular and clinical genetics

• Published in: Anticancer research Vol. 20; no. 6C; p. 4841
• Main Authors: Russo, A, Zanna, I, Tubiolo, C, Migliavacca, M, Bazan, V, Latteri, M A, Tomasino, R M, Gebbia, N
• Format: Journal Article
• Language: English
• Published: Greece 01.11.2000
• Subjects: Animals; Biomarkers, Tumor - genetics; Female; Genes, Tumor Suppressor; Genetic Predisposition to Disease; Humans; Male; Models, Genetic; Neoplasms - genetics; Pedigree; Risk Assessment
• ISSN: 0250-7005

This review focuses on the functional role and structural features of the genes involved in common hereditary cancers. Most of these tumors are sporadic and the genetic alterations responsible for their genesis take place over several cell generations; nevertheless, 5 to 10% of the human tumors are hereditary, with a rapid development. Cancer susceptibility genes have been classified as "gatekeepers" (e.g. RB1, ki-ras) and "caretakers" (e.g. hMLH1 and hMSH2, BRCA1). The first step in identifying individuals at high risk of developing a specific inherited form of cancer, and who should therefore undergo genetic tests, is the detailed construction of family history (an accurate cancer family history that includes at least three generation pedigrees, an appropriate cancer risk assessment and an effective genetic counseling). At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenomatous polyposis, ret for medullary thyroid carcinoma, p53 for the Li-Fraumeni syndrome, p16 for melanoma and RB1 for retinoblastoma. In conclusion, the development of new diagnostic tests will permit a more accurate assessment of risk in individuals who have not so far shown any sign or symptom of the disease.